## **ICMJE DISCLOSURE FORM**

Date:			8/9/2021			
Your Name:			Jan Palmen			
Manuscript Title:			Prevalentie en medicamenteuze behandeling van mensen met Diabetes Mellitus type 2 en zeer hoog risico op hart- en vaatziekten			
Maı	nuscript Number (if k	(nown):	Not known			
content of your manuscript. "Relate affected by the content of the manu indicate a bias. If you are in doubt a The author's relationships/activities, epidemiology of hypertension, you sthat medication is not mentioned in						
In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.						
			entities with whom you have this hip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	PHARM	O Institute for Drug Outcome Research se generation Lead AstraZeneca ints for Review proposal, protocol and interpretation results Input manuscript and co-authorship	lick the tab key to add additional rows.		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	PHARM Evidence	O Institute for Drug Outcome Research se generation Lead AstraZeneca hts for Review proposal, protocol and interpretation results			
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	PHARM Evidence	O Institute for Drug Outcome Research se generation Lead AstraZeneca its for Review proposal, protocol and interpretation results Input manuscript and co-authorship  Time frame: past 36 month			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payment made to you or to your institution)	nts were
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	□ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options		None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None		
13	Other financial or non-financial interests		None		
Please place an "X" next to the following statement to indicate your agreement:					

3